Bausch Health Companies Inc. (BHC) 2017 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning. My name is Chris, and I will be your conference operator today. At this time, I would like to welcome everyone to the Valeant Third Quarter 2017 Earnings Conference Call. (Operator Instructions)

    各位早安。我叫 Chris,今天將擔任本次電話會議的接線員。此刻,我謹代表公司歡迎各位參加 Valeant 2017 年第三季財報電話會議。(接線員指示)

  • Art Shannon, Senior Vice President and Head of Investor Relations, you may begin your conference.

    投資人關係資深副總裁暨主管 Art Shannon,您可以開始會議。

  • Arthur J. Shannon - Senior VP and Head of IR & Communications

    Arthur J. Shannon - Senior VP and Head of IR & Communications

  • Thank you, Chris, good morning, everyone, and welcome to Valeant Pharmaceuticals Third Quarter 2017 Financial Results Conference Call. Participating on today's call are Chairman and Chief Executive Officer, Joe Papa; and Chief Financial Officer, Paul Herendeen. In addition to this live webcast, a copy of today's slide presentation and replay of this conference call will be available on our website under the Investor Relations section.

    謝謝你,Chris。各位早安,歡迎參加 Valeant Pharmaceuticals 2017 年第三季財務結果電話會議。今天與會者包括董事長兼執行長 Joe Papa,以及財務長 Paul Herendeen。除本次即時網路直播外,今日簡報投影片的副本以及本次電話會議的重播,將可於我們網站「投資人關係」專區取得。

  • Before we begin, we would like to remind you that our presentation today contains forward-looking information. We would like -- we would ask you to take a moment to read through the forward-looking statement legend at the beginning of our presentation as it contains important information.

    在開始之前,我們提醒各位,今天的簡報包含前瞻性資訊。我們想——我們請各位花一點時間閱讀簡報開頭的前瞻性聲明說明,因為其中包含重要資訊。

  • The presentation contains non-GAAP financial measures. For more information about these measures, please refer to Slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix to the presentation posted on our website.

    本簡報包含非 GAAP 財務衡量指標。如需了解這些指標的更多資訊,請參閱簡報第 2 頁。非 GAAP 調節表可在我們網站所發布之簡報附錄中找到。

  • Finally, the financial guidance in this presentation is effective as of today only. It is our policy to generally not update guidance until the following quarter and not to update or affirm guidance other than through broadly disseminated public disclosure.

    最後,本簡報中的財務指引僅以今日為準。我們的政策通常是在下一季之前不更新指引,且除透過廣泛發布的公開揭露外,不更新或確認指引。

  • With that, it's my pleasure to turn the call over to Joe.

    接下來,我很高興把電話會議交給 Joe。

  • Joseph C. Papa - Chairman & CEO

    Joseph C. Papa - Chairman & CEO

  • Thank you, Art. Before we jump into the quarter, let me first review the topics for today's call. I'll start with the progress since our last earnings call. I'll then turn the call over to our CFO, Paul Herendeen, to review our third quarter financial results in detail and go through the updates to our 2017 guidance. Then I'll briefly cover some of the business and pipeline highlights.

    謝謝你,Art。在我們進入本季內容之前,我先回顧今天電話會議的議程。我將先談自上次財報電話會議以來的進展。接著我會把電話交給我們的財務長 Paul Herendeen,請他詳細說明第三季財務結果,並說明我們對 2017 年指引的更新。然後我會簡要分享一些業務與產品研發管線的重點。

  • Starting with Slide 5. This is the checklist we use to measure our progress against the goals for the turnaround. As I've said before, transforming Valeant will not happen overnight. It will take a multiyear process to require the hard work of thousands of people taking incremental steps to build the right foundation for the company's future success.

    先從第 5 頁投影片開始。這是我們用來衡量重整目標進度的檢核表。如我先前所說,改造 Valeant 不會一蹴可幾。這將是一個多年期的過程,需要數千名員工的辛勤努力,透過逐步的增量行動,為公司未來的成功建立正確的基礎。

  • Since I joined Valeant 18 months ago, we focused on addressing the key action steps, including new leadership, a renewed focus on quality and innovation, and creating a culture that is in line with the people who use our health care products to improve their lives.

    自我在 18 個月前加入 Valeant 以來,我們專注於處理關鍵行動步驟,包括引進新領導團隊、重新聚焦品質與創新,以及打造一種文化,使其與使用我們醫療保健產品、以改善生活的人們一致。

  • While there is more to do to complete the turnaround to be clear, Valeant today is a stronger company than it was a year ago. We've recruited a new management team, introduced new reportable business segments and stabilized the company.

    需要明確的是,為完成重整仍有更多工作要做;但今日的 Valeant 已比一年前更為強健。我們延攬了新的管理團隊、導入新的可報導事業部門,並使公司營運趨於穩定。

  • Now as we're nearing the middle of the turnaround phase, we have taken actions to strengthen our balance sheet, simplify our business and allocate resources efficiently. 21,000 employees at Valeant are focused on the successful turnaround of Valeant. In fact, every time an analyst criticizes our company, it further unites our Valeant team.

    如今,隨著我們接近重整階段的中段,我們已採取行動以強化資產負債表、簡化業務,並有效配置資源。Valeant 的 21,000 名員工都專注於 Valeant 的成功重整。事實上,每當有分析師批評我們公司,反而更能凝聚我們 Valeant 團隊。

  • How do I know? We recently completed a global employee survey. The results are outstanding. 82% of the respondents consider Valeant to be on the right track for growth, an increase from last year. Additionally, 92% of the employees would recommend Valeant as a great place to work, which is up 12 percentage points from last year and significantly above the normal for this specific survey question.

    我怎麼知道?我們最近完成了一項全球員工調查。結果非常出色。82% 的受訪者認為 Valeant 正走在正確的成長軌道上,較去年提升。此外,92% 的員工會推薦 Valeant 是一個很棒的工作場所,較去年增加 12 個百分點,且顯著高於此題在該調查中的一般水準。

  • These endorsements of our business direction and culture, along with our strong third quarter performance, demonstrates our continued progress for the turnaround of Valeant.

    這些對我們業務方向與文化的肯定,加上我們第三季強勁的表現,顯示我們在 Valeant 重整方面持續取得進展。

  • Over to Slide 6. A quick summary of the quarter. It was a great quarter, with revenues above expectations, with EBITDA above expectations and with adjusted net income above expectations. This allows us to maintain EBITDA guidance, notwithstanding the completion of additional asset sales.

    接著看第 6 頁投影片,快速總結本季表現。這是一個非常出色的季度:營收高於預期、EBITDA 高於預期,調整後淨利也高於預期。因此,即使我們完成了額外的資產出售,我們仍得以維持 EBITDA 指引。

  • In terms of execution, once again, our 2 largest business are doing great and are now showing solid organic growth of 6% due to better resource allocation and additional investments. Our largest segment, Bausch + Lomb/International, which represents approximately 57% of our revenues in the quarter, delivered another quarter of solid growth. The business, which is flat to declining a year ago, grew 6% organically in the third quarter as compared to 3Q 2016. This is the third consecutive quarter of 6% organic revenue growth.

    就執行面而言,再次地,我們兩大業務表現非常好,並因更佳的資源配置與額外投資,現已展現 6% 的穩健有機成長。我們最大的事業部門 Bausch + Lomb/International,在本季約占營收 57%,再度交出穩健成長的一季。該業務相較一年前持平至下滑,但在第三季相較 2016 年第三季有機成長 6%。這是連續第三季達成 6% 的有機營收成長。

  • Salix, the largest part of the Branded Rx segment, represented about 20% of the company's revenue, also generated organic revenue of 6% largely due to the uptick of XIFAXAN that increased revenue growth by 5% and the launch of RELISTOR Tablets, which drove prescription growth by 61%.

    Salix 作為品牌處方藥(Branded Rx)部門中最大的一部分,約占公司營收 20%,同樣創造 6% 的有機營收成長,主要受惠於 XIFAXAN 的回升,使營收成長提高 5%,以及 RELISTOR 錠劑上市,帶動處方量成長 61%。

  • Moving now on to our product pipeline. We had another active quarter. Last week, the FDA improved VYZULTA, which is great news for patients with open-angle glaucoma. Our team is busy preparing for the commercial launch, and we expect the product to be available in the fourth quarter of 2017.

    接著談我們的產品研發管線。我們又度過了一個活躍的季度。上週,FDA 核准了 VYZULTA,這對開角型青光眼患者而言是個好消息。我們的團隊正忙於準備商業化上市,我們預期該產品將於 2017 年第四季上市供應。

  • Also, we recently received a June 18, 2018 PDUFA date for IDP-118, a topical lotion for the treatment of plaque psoriasis that we believe has the potential to be a game changer. I'll talk more about IDP later.

    此外,我們最近也收到 IDP-118 的 PDUFA 日期為 2018 年 6 月 18 日;IDP-118 是一款用於治療斑塊型乾癬的外用乳液,我們相信它有潛力成為改變遊戲規則的產品。我稍後會再多談 IDP。

  • Our team introduced Biotrue ONEday for astigmatism daily disposable contact lenses in 20 countries in Europe, and the Thermage system received clearance from the FDA to noninvasively smooth skin on the face, eyes and body.

    我們的團隊已在歐洲 20 個國家推出用於散光的 Biotrue ONEday 每日拋棄式隱形眼鏡;同時,Thermage 系統也獲得 FDA 核准,可用非侵入方式使臉部、眼周與身體肌膚更平滑。

  • There are enormous opportunities for B + L in Asia, where our lens care portfolio has the leading market share and is growing. In September, I visited with the team who launched AQUALOX contact lenses in Japan. They are doing an outstanding job with this launch, and our new ULTRA monthly contact lenses are currently under review in China.

    在亞洲,B + L 擁有龐大的機會;我們的隱形眼鏡護理產品組合具備領先的市占率且持續成長。9 月時,我拜訪了在日本推出 AQUALOX 隱形眼鏡的團隊。他們在這次上市表現非常出色,而我們新的 ULTRA 月拋隱形眼鏡目前正在中國審查中。

  • On to Slide 7, let's turn to the progress we have made in our efforts to reduce debt and divest noncore assets. First, we are pleased to report that we reduced total debt by approximately $6 billion since the end of the first quarter of 2016.

    接著看第 7 張投影片,讓我們回顧在降低負債與處分非核心資產方面所取得的進展。首先,我們很高興報告,自 2016 年第一季末以來,我們已將總負債降低約 60 億美元。

  • In addition, we've exceeded our commitment to pay down $5 billion of debt from divestiture proceeds and free cash flow by February 2018. And we've delivered on that commitment earlier than we previously had stated.

    此外,我們已在 2018 年 2 月前,透過資產處分所得與自由現金流償還 50 億美元負債的承諾,且已超額達成。而且我們比先前所述更早完成了這項承諾。

  • Moving on to asset sales. Since the beginning of 2015, we have announced approximately $3.8 billion in total asset sales. In addition, we announced yesterday that we are divesting Sprout Pharmaceuticals. While we believe ADDYI may represent an opportunity, women's health does not fit within our core business portfolio, which are eye health, GI and dermatology.

    接著談資產出售。自 2015 年初以來,我們已宣布約 38 億美元的資產出售總額。另外,我們昨天宣布將處分 Sprout Pharmaceuticals。雖然我們認為 ADDYI 可能代表一項機會,但女性健康並不符合我們的核心業務組合;我們的核心業務為眼科健康、腸胃(GI)與皮膚科。

  • By proactively managing our working capital, we have continued to provide positive results in the quarter and year-to-date performance. From September 30, 2016, to September 30, 2017, we've reduced working capital days by approximately 45 days and inventory days by (technical difficulty) on hand by approximately 30 days.

    透過主動管理營運資金,我們在本季及年初至今的表現持續交出正面成果。從 2016 年 9 月 30 日到 2017 年 9 月 30 日,我們將營運資金天數降低約 45 天,並將庫存天數(技術問題)在手天數降低約 30 天。

  • We've taken a number of actions that have resulted in greater financial flexibility that can create more opportunities going forward. Thanks to the hard work of Paul Herendeen, Linda LaGorga and their teams, we have no debt maturities until 2020 and no mandatory amortization requirements now or in the future.

    我們採取了多項行動,提升了財務彈性,並可在未來創造更多機會。多虧 Paul Herendeen、Linda LaGorga 及其團隊的努力,我們在 2020 年之前沒有到期債務,且目前或未來都沒有強制攤還要求。

  • Turning now to Slide 8. For the past several quarters, we've been dealing with 3 legacy challenges: the Ortho Dermalogics business, supply chain issues and legacy legal cases. We've made measurable progress in addressing each of these areas, and we have a lot of positive developments to share today.

    現在轉到第 8 張投影片。過去幾個季度,我們一直在處理 3 項歷史遺留挑戰:Ortho Dermalogics 業務、供應鏈問題,以及歷史法律案件。我們在上述各領域都取得了可衡量的進展,今天也有許多正面進展要與各位分享。

  • First, we continue to make progress stabilizing the dermatology business and advancing the pipeline. The launch of SILIQ in third quarter introduced the lowest-priced injectable biologic for moderate-to-severe plaque psoriasis in the United States.

    首先,我們持續在穩定皮膚科業務並推進研發管線方面取得進展。第三季推出的 SILIQ,為美國中重度斑塊型乾癬中價格最低的可注射生物製劑。

  • Just a few months post launch, 75% of dispensed prescriptions are covered by managed care, and we recently presented 2-year findings demonstrating the impressive long-term efficacy profile of SILIQ. Dermatology pricing is continuing to stabilize.

    上市後僅數個月,已配藥處方中有 75% 受到管理式醫療給付涵蓋;我們近期也發表了 2 年期研究結果,顯示 SILIQ 令人印象深刻的長期療效特徵。皮膚科定價持續趨於穩定。

  • Finally, advancing innovative new products through our pipeline will be the key growth driver of the dermatology business. In addition to the filing acceptance for IDP-118, we submitted IDP-121 for acne to the FDA and are preparing to submit IDP-122, another psoriasis product, by the end of the year.

    最後,透過我們的研發管線推進創新新產品,將是皮膚科業務的關鍵成長驅動力。除了 IDP-118 的申請已獲受理之外,我們也已向 FDA 提交治療痤瘡的 IDP-121,並正準備在年底前提交另一項乾癬產品 IDP-122。

  • Turning now to our manufacturing facilities. Our focus on and investment in supply chain and quality leadership has made a huge difference. A year ago, Rochester, New York and the Bridgewater, New Jersey facilities were operating with warning letters related to quality control manufacturing practices.

    接著談我們的製造設施。我們對供應鏈與品質領導的聚焦與投資,帶來了巨大的改變。一年前,紐約州羅徹斯特與新澤西州布里奇沃特的設施,因品質管制製造作業而收到警告信。

  • Now we resolved the 2 warning letters, and the FDA has upgraded our Tampa, Florida facility from an OAI to VAI or Voluntary Action Indicated status. We've also made progress in simplifying our supply chain by reducing the number of manufacturing sites by 25% and discontinuing approximately 1,300 SKUs.

    目前我們已解決這 2 封警告信,且 FDA 已將我們佛羅里達州坦帕的設施從 OAI 升級為 VAI(Voluntary Action Indicated,建議自願改善)狀態。我們也透過將製造據點數量減少 25%,並停止約 1,300 個 SKU,來簡化供應鏈。

  • Finally, we've been able to deal with some of the legacy legal cases the company has been facing since before I joined in May 2016. We achieved dismissals and/or positive outcomes in 21 litigations and investigations relating to historical matters since the end of Q2, including the dismissal of action related to a September 2015 DOJ investigation regarding Bausch + Lomb and a settlement and dismissal of the Depomed/GLUMETZA royalty dispute relating to the royalty period starting in October 2013 through December 2015. Christina Ackermann and her legal team have done a great job resolving these models -- these matters.

    最後,我們也得以處理公司自我於 2016 年 5 月加入之前就一直面臨的一些歷史法律案件。自第二季末以來,針對歷史事項的 21 件訴訟與調查,我們已取得撤案及/或正面結果,其中包括撤銷與 2015 年 9 月 DOJ 對 Bausch + Lomb 的調查相關之訴,以及就 Depomed/GLUMETZA 權利金爭議(涵蓋自 2013 年 10 月起至 2015 年 12 月的權利金期間)達成和解並撤案。Christina Ackermann 與其法務團隊在解決這些模組——這些事項方面做得非常出色。

  • On Slide 9, we presented Q3 revenue and adjusted EBITDA for each of the business segments. I want to call out the fact that Bausch + Lomb/International and Salix, which together represents 77% of our revenue this quarter, delivered strong top line performance for the second quarter in a row. Last quarter, these 2 businesses represented approximately 73% of revenues. Now they're at 77%.

    在第 9 張投影片中,我們呈現了各業務部門的第三季營收與調整後 EBITDA。我想特別指出,Bausch + Lomb/International 與 Salix 兩項業務合計占本季營收的 77%,且已連續第二季交出強勁的營收成長表現。上季,這兩項業務約占營收的 73%。現在則達到 77%。

  • I'll provide more comments on each of these businesses after Paul reviews our financial results. Now I'll turn it over to Paul.

    在 Paul 檢視我們的財務結果之後,我會再對各項業務補充更多評論。現在我把時間交給 Paul。

  • Paul S. Herendeen - EVP of Finance & CFO

    Paul S. Herendeen - EVP of Finance & CFO

  • Thank you, Joe. Before I get started, I do want to remind people what we mean when we talk about organic change. That means our actual results adjusted for fluctuation in FX rates, what we call constant currency, and further adjusted to remove the impact of divested assets or businesses. Organic change highlights the fundamental growth or decline of our go-forward businesses.

    謝謝你,Joe。在我開始之前,我想先提醒大家,我們所說的「有機變動」是什麼意思。也就是將實際結果調整匯率波動(我們稱為固定匯率,constant currency),並進一步剔除已處分資產或業務的影響。有機變動凸顯我們未來持續經營業務的基本成長或下滑。

  • I want to start by providing a little color on the quarter starting with a walk down of the P&L on Slide 10. Total revenues were down 10% versus Q3 of 2016. Adjusted for FX and divested assets, again what we refer to as organic change, we posted a 4% decline in revenue.

    我想先從第 10 張投影片的損益表拆解,為本季表現提供一些補充說明。總營收較 2016 年第三季下滑 10%。若調整匯率與已處分資產(也就是我們所稱的有機變動),營收下滑 4%。

  • We saw about 90 basis points of growth in realized net prices compared with the prior year quarter. And importantly, we saw improved net pricing in both the B + L/International segment and the Branded Rx segment. Total volumes declined nearly 5%, with 80% of that decline coming from the expected impact of the LOE asset shown in the appendix to the slides.

    與去年同期相比,我們看到已實現的淨價格約成長 90 個基點。更重要的是,我們在 B + L/International 部門與 Branded Rx 部門都看到淨定價改善。總銷量下滑近 5%,其中 80% 的下滑來自投影片附錄所示、符合預期的 LOE 資產影響。

  • Setting aside the LOE assets, the balance of our business was basically flat with the third quarter 2016 as the growth in our B + L/International segment and the Salix business, which, as Joe said, together accounted for 77% of our revenues, were up 6% organically, offsetting volume declines in our Dermatology business and our Diversified segment.

    若先不考慮 LOE 資產,我們其餘業務與 2016 年第三季基本持平;其中 B + L/International 部門與 Salix 業務(如 Joe 所說,兩者合計占我們營收的 77%)有機成長 6%,抵銷了皮膚科業務與多元化部門的銷量下滑。

  • Our gross margin in the quarter declined by some 330 basis points, mainly due to mix, unfavorable FX in our non-U. S. businesses and the impact of the $13 million settlement of the royalty audit on GLUMETZA. As Joe said that it's important the GLUMETZA settlement cover the period from 2013 through 2015, and it reduced our gross margin in the quarter by some 60 basis points.

    本季毛利率下滑約 330 個基點,主要原因為產品組合影響、我們非美國業務的不利匯率因素,以及 GLUMETZA 權利金稽核 1,300 萬美元和解的影響。如 Joe 所說,GLUMETZA 的和解涵蓋 2013 年至 2015 年期間,並使本季毛利率降低約 60 個基點。

  • The revenue declines in our Diversified segment, driven mainly by the LOE products, fed a roughly 630 basis point decline in gross margins in that segment, which accounts for the bulk of the company-wide reduced gross margin.

    我們多元化事業部的營收下滑,主要受 LOE(專利到期)產品所驅動,導致該事業部毛利率約下降 630 個基點,而該事業部占公司整體毛利率下滑的大部分。

  • Selling and A&P together increased roughly 1%. You should recall that, in 2017, we have chosen to add to our sales forces in the Salix and women's health businesses, and the cost of those incremental investments more than offset other successful efforts to align our total selling and A&P costs with our current revenue levels.

    銷售與 A&P(廣告與促銷)合計約增加 1%。各位應該記得,2017 年我們選擇在 Salix 與女性健康業務擴增銷售團隊,而這些新增投資的成本,已超過我們在其他方面成功推動、使整體銷售與 A&P 成本與目前營收水準對齊的努力所帶來的節省。

  • G&A costs decreased by 20%. In the current year quarter, we had an elevated level of spending for outside services in support of our efforts to prepare assets for divestment and to complete the separation of previously sold assets.

    G&A(一般及行政)成本下降 20%。在本年度本季,我們為了支援資產待出售的準備工作,以及完成先前已出售資產的分離作業,對外部服務的支出水準偏高。

  • Legal expenses also increased year-over-year. However, we incurred significantly less recruiting and retention costs in the current year quarter, which led to the favorable variance in G&A.

    法律費用也較去年同期增加。不過,本年度本季我們發生的招募與留任成本顯著較少,因而帶來 G&A 的有利差異。

  • In R&D, our investment in the quarter was down some $20 million compared with the prior year quarter. Very important. As we go through the process of divesting assets, we have been terminating R&D projects related to those businesses. The process of redeploying those freed up resources has been slower than we would have liked, but we want to be deliberate to ensure that the mix of the continuing projects is consistent with our evolving view of priorities amongst our core business units.

    在研發方面,本季投資較去年同期減少約 2,000 萬美元。這點非常重要。在我們進行資產剝離的過程中,已終止與這些業務相關的研發專案。將釋放出的資源重新部署的進度比我們希望的更慢,但我們希望審慎為之,以確保持續進行的專案組合,符合我們對核心事業單位之間優先順序的最新觀點。

  • To be very clear, we're not intentionally reducing our investment in R&D. We fully expect to spend more in 2018 than we did in 2016. With the impact of 2017 divestitures, we are simply experiencing a time lag as we work to reallocate resources to our list of potential projects. In the quarter, we posted adjusted EBITDA of $951 million.

    我要非常清楚地說,我們並非刻意降低研發投資。我們完全預期 2018 年的研發支出將高於 2016 年。在 2017 年剝離資產的影響下,我們只是於將資源重新分配至潛在專案清單的過程中,出現時間落差。本季我們的調整後 EBITDA 為 9.51 億美元。

  • Before I move on to the segments, I do want to spend a minute addressing how our GAAP net income flipped from a $1.2 billion loss in the prior year quarter to a $1.3 billion of net income in the current year quarter. There's a lot happening in both the prior year quarter and the current quarter, particularly with respect to our intangible assets, goodwill, contingent consideration and our tax accounts, none of which impact what we believe is our most important performance metric, adjusted EBITDA.

    在我進入各事業部之前,我想花一點時間說明:我們的 GAAP 淨利為何從去年同期的 12 億美元虧損,轉為本年度本季 13 億美元的淨利。去年同期與本季都有許多事項在發生,特別是與無形資產、商譽、或有對價以及稅務科目相關;而這些都不影響我們認為最重要的績效指標——調整後 EBITDA。

  • It's worth spending a minute or 2 on how these items impacted our Q3 2017 results. In this quarter, we reclassified Sprout as an asset held for sale. That triggered the write-down of intangible assets associated with Sprout and a goodwill impairment in our Branded Rx segment.

    值得花一到兩分鐘說明這些項目如何影響我們 2017 年第三季的結果。本季我們將 Sprout 重新分類為待出售資產。這觸發了與 Sprout 相關的無形資產減損,以及我們品牌處方藥(Branded Rx)事業部的商譽減損。

  • Additionally, we also had a reversal of the acquisition-related contingent consideration associated with Sprout. These items together significantly reduced our GAAP pretax income in the quarter. More than offsetting those pretax charges was the recognition of a significant income tax benefit in the quarter.

    此外,我們也回轉了與 Sprout 相關、併購所產生的或有對價。上述項目合計使本季 GAAP 稅前利益顯著降低。而足以抵銷這些稅前費用的,是本季認列了一筆可觀的所得稅利益。

  • In the fourth quarter last year, we initiated a restructuring of our global organization with the goals of reducing operating complexity and strengthening our tax structure.

    去年第四季,我們啟動了全球組織重整,目標是降低營運複雜度並強化我們的稅務架構。

  • In Q3 of '17, we completed the restructuring, resulting in the reversal of certain deferred tax assets and liabilities, which resulted in the large tax benefit being recorded in the quarter.

    在 2017 年第三季,我們完成了該重整,並回轉了部分遞延所得稅資產與負債,因此在本季記錄了大額的稅務利益。

  • I'm sure there'll be questions about the impairments of our intangible assets and goodwill and the tax recovery. I'll point you to the disclosures that will be contained in our 10-Q, which we expect to file shortly, and I'll emphasize, again, these items do not impact cash or our adjusted EBITDA.

    我相信大家會對無形資產與商譽的減損,以及稅務回轉提出問題。我請各位參考我們預計不久後提交的 10-Q 中所載的揭露內容;我也再次強調,這些項目不影響現金或我們的調整後 EBITDA。

  • With that behind us, let's turn to the segments, beginning on Slide 11. The B + L/International segment posted another solid quarter with organic growth of 6% versus Q3 of '16. Three of the 4 B + L businesses delivered organic growth led by Global Vision Care, up 8% organically, driven by 10% -- increase of 10% in volume and a 2% decrease in realized pricing; Global Consumer, which was up 6% organically all due to volume as prices were flat quarter-to-quarter; and Global Surgical, which was up 2% organically, up 4% in volume, offset by minus 2% in realized pricing. Our Global Ophtho Rx business was down 9% organically, but 7% of that was a volume decline driven by a reduction in U.S. pipeline inventories relative to Q3 of 2016.

    在此之後,讓我們轉到各事業部,從投影片 11 開始。B + L/國際事業部本季再度繳出穩健表現,相較 2016 年第三季有 6% 的有機成長。四個 B + L 業務中有三個實現有機成長,其中以全球視力照護領先,有機成長 8%,主要由 10% 的銷量成長與 2% 的實現價格下降所驅動;全球消費品有機成長 6%,完全來自銷量,因為價格季對季持平;全球手術有機成長 2%,銷量成長 4%,但被實現價格下降 2% 所抵銷。我們的全球眼科處方藥(Ophtho Rx)業務有機下滑 9%,其中 7% 的下滑來自銷量下降,主因是美國通路管線庫存相較 2016 年第三季有所降低。

  • The International grouping, containing all of our non-U. S. pharma businesses, grew 16% mainly due to 2 factors. First, we had a favorable comparison versus the prior year quarter when we absorbed a meaningful contraction of pipeline inventories in Eastern Europe, mainly Poland. And second, we realized higher, realized prices during the quarter, mainly coming out of Egypt, where were able to get governmental approval to increase prices to help offset the impact of the devaluation of the currency back in 2016.

    國際組合(包含我們所有非美國的製藥業務)成長 16%,主要由兩項因素帶動。第一,與去年同期相比基期有利,因為去年同期我們吸收了東歐(主要是波蘭)通路管線庫存的明顯收縮。第二,本季我們實現了較高的實現價格,主要來自埃及;我們取得政府核准調高價格,以協助抵銷 2016 年貨幣貶值的影響。

  • Gross margins in this segment were down from the prior year about 70 basis points with FX being a factor. Selling and A&P expenses together were slightly unfavorable on a constant currency basis, about 1%.

    本事業部毛利率較去年同期下降約 70 個基點,匯率為其中一項因素。銷售與 A&P 費用合計以固定匯率計略為不利,約 1%。

  • I submit that our expense control across this segment has been quite good. In a nutshell, a solid quarter for the B + L/International segment.

    我認為我們在此事業部的費用控管做得相當不錯。簡而言之,B + L/國際事業部本季表現穩健。

  • On to the Branded Rx segment on Slide 12. Reported revenues were down 17%. However, the divestitures of Ruconest and Dendreon accounted for 10 percentage points of that decline. So the organic decline was 7%.

    接著看投影片 12 的品牌處方藥(Branded Rx)事業部。報告營收下降 17%。不過,Ruconest 與 Dendreon 的剝離占了其中 10 個百分點的降幅。因此,有機降幅為 7%。

  • Organic growth in Salix of 6% and dentistry of 10% were more than offset by the 34% year-over-year decline in the Derm business. The main issue with our Dermatology business continues to be a difficult reimbursement environment for our legacy products. The good news is that pricing of the business has stabilized. Realized prices across the Dermatology business were flat compared with the third quarter last year.

    Salix 的 6% 有機成長與牙科的 10% 有機成長,仍不足以抵銷皮膚科業務年對年 34% 的下滑。我們皮膚科業務的主要問題仍是傳統產品面臨艱困的給付/報銷環境。好消息是該業務的定價已趨於穩定。皮膚科業務的實現價格相較去年第三季持平。

  • Sequentially, unit volumes improved slightly, but compared with the year ago, volumes are up more than 32%. Note that the third quarter's typically the strongest seasonal quarter for our Derm portfolio, particularly our acne products, so keep that in mind when you're thinking about Q4.

    依序來看,單位銷量略有改善,但與去年同期相比,銷量增加超過32%。請注意,第三季通常是我們皮膚科產品組合中季節性最強的一季,特別是我們的痤瘡產品,因此在思考第四季時請將此納入考量。

  • With realized net pricing stabilizing, we now shift our attention to driving volume increases for our legacy portfolio, having a successful launch of SILIQ and being well prepared for future launches coming out of our R&D pipeline such as IDP-118, IDP-121 and IDP-122. The factor that will change our outlook in Dermatology is innovation, and we're fortunate that we have a panoply of late-stage derm R&D projects that can put us in position to return this important business to growth mode.

    隨著已實現淨定價趨於穩定,我們現在將重點轉向推動既有產品組合的銷量成長、成功推出SILIQ,並為研發管線中未來的上市產品(如IDP-118、IDP-121與IDP-122)做好充分準備。將改變我們皮膚科展望的因素是創新;我們很幸運擁有一系列後期皮膚科研發專案,可使我們有機會讓這項重要業務重回成長軌道。

  • The largest component of our Branded Rx segment, Salix, grew 6% organically, up 10% in pricing and down 5% in volume. The 2 main drivers in Salix were XIFAXAN and GLUMETZA. XIFAXAN was up 5% year-over-year on an 8% increase in realized pricing, offset by a 4% reported decline in volume. The difference between reported 4% volume decline and the plus 3% year-over-year growth in extended unit TRx with XIFAXAN is fully explained by a relative contraction in pipeline inventories.

    我們品牌處方藥(Branded Rx)部門中最大的組成部分Salix,有機成長6%,其中定價上升10%,銷量下降5%。Salix的兩大主要驅動因素是XIFAXAN與GLUMETZA。XIFAXAN年增5%,已實現定價上升8%,但被報告銷量下降4%所抵銷。報告的銷量下降4%與XIFAXAN延伸單位TRx年增3%之間的差異,完全可由通路管線庫存相對收縮所解釋。

  • GLUMETZA sales remain strong right until the end of the quarter, at which time we saw demand shift away from our brand to our authorized generic that is in our Diversified segment. Dentistry revenues in the Branded Rx segment were up 10% organically mainly due to our relaunch of Neutrasal.

    GLUMETZA的銷售一直強勁直到季末;在季末時,我們看到需求從我們的品牌轉向我們的授權學名藥(authorized generic),該產品歸在我們的多元化(Diversified)部門。品牌處方藥部門中的牙科營收有機成長10%,主要來自我們重新推出Neutrasal。

  • Branded Rx selling and A&P expenses together increased by 5% or about $6 million. As I said, when looking at our consolidated results, this is mainly due to the increased cost of the Salix and women's health care sales forces, offset in part by successful efforts to rationalize costs in Ortho Dermatologics.

    品牌處方藥的銷售費用與A&P費用合計增加5%,約增加600萬美元。如我所說,在檢視我們的合併結果時,這主要是因Salix與女性健康照護銷售團隊成本增加所致,部分被Ortho Dermatologics成功精簡成本的努力所抵銷。

  • On to the Diversified segment on Slide 13, where the story of the roughly 29% year-over-year decline are 2 things. First, the LOE assets, which accounted for 18 percentage points of the decline; and second, our generics business, where we saw the predictable declines associated with that portfolio.

    接著看第13頁的多元化部門,其年對年約29%的下滑主要由兩件事構成。第一是LOE資產,貢獻了下滑中的18個百分點;第二是我們的學名藥業務,我們看到該產品組合所伴隨的可預期下滑。

  • On to Slide 14, where we continue to make -- which is the balance sheet, where we continue to make progress reducing the quantum of our debt through cash generated by the business and asset sales. I'd point out that we ended the quarter with a high cash balance with the proceeds from the iNova sale sitting in cash at quarter close.

    接著看第14頁,也就是資產負債表;我們持續透過業務產生的現金與資產出售,降低我們債務的規模。我要指出的是,我們在季末的現金餘額偏高,因為iNova出售所得在季末時仍以現金形式持有。

  • Subsequent to September 30, we used $923 million of the iNova proceeds to repay senior secured term loans. And last week, we used another $125 million of cash to prepay more senior secured term loans.

    在9月30日之後,我們使用iNova出售所得中的9.23億美元償還優先擔保定期貸款。而在上週,我們又使用另外1.25億美元現金提前償還更多優先擔保定期貸款。

  • Moving to Slide 15. This shows a pro forma snapshot of our debt maturities and mandatory amortization as of today. Key takeaways. We have no mandatory amortization remaining on our term loans and our next debt maturity is out in 2020.

    接著看第15頁。這張圖顯示截至今日,我們債務到期與強制攤還的備考(pro forma)概況。重點結論:我們的定期貸款已無剩餘的強制攤還,而下一筆債務到期日在2020年。

  • Managing our debt load requires that we continually look for ways to address our debt stack in 2020 and beyond. The good work we've completed over the last, say, 6 quarters has provided us with the time and flexibility to be successful in managing through a challenging situation.

    管理我們的債務負擔,要求我們持續尋找方法來處理2020年及以後的債務結構。我們在過去大約6個季度完成的良好工作,為我們在充滿挑戰的情況下成功應對提供了時間與彈性。

  • Next, our cash flow summary, Slide 16. I'm going to repeat a couple of things Joe mentioned because they're important. We generated $490 million of cash from operations in the quarter; and year-to-date, we generated more than $1.7 billion. An important part of this effort has been a focus on improving our working capital efficiency, and we made excellent progress there.

    接下來是我們的現金流量摘要,第16頁。我會重申Joe提到的幾點,因為它們很重要。本季我們由營運產生4.90億美元現金;年初至今,我們產生超過17億美元。這項努力的重要部分在於聚焦提升營運資金效率,而我們在這方面取得了極佳進展。

  • From September 30 of '16 to '17, we reduced our working capital by roughly 45 days and our inventory by more than 30 days on hand. Working capital efficiency is a high priority for us, and we intend to make additional progress on this front to unlock cash from the balance sheet that we can use to reduce debt.

    從2016年9月30日到2017年9月30日,我們將營運資金縮減約45天,庫存周轉天數(days on hand)降低超過30天。營運資金效率是我們的高度優先事項,我們打算在此面向取得更多進展,從資產負債表釋放現金以用於降低債務。

  • Turning now to our guidance slide, Slide 17. Today, we revised our revenue and adjusted EBITDA guidance to reflect the impact of the closed iNova divestiture, the imminent Obagi divestiture and for a modest improvement in the outlook for the basket of LOE assets detailed in the appendix to our slides.

    現在轉到我們的財測頁,第17頁。今天,我們修訂了營收與調整後EBITDA指引,以反映已完成的iNova剝離、即將完成的Obagi剝離,以及對附錄中所詳述之LOE資產組合展望的小幅改善。

  • The balance of our business is tracking slightly ahead of our expectations, and we've narrowed our guidance ranges to $150 million for both revenue and adjusted EBITDA. Our revised guidance for 2017 is for revenue in the range of $8.65 billion to $8.80 billion and for adjusted EBITDA in the range of $3.60 billion to $3.75 billion.

    我們其餘業務的表現略優於預期,我們也將營收與調整後EBITDA的指引區間各自收斂至1.50億美元。我們修訂後的2017年指引為:營收介於86.5億至88.0億美元,調整後EBITDA介於36.0億至37.5億美元。

  • We are pleased that we are able to maintain our guidance for adjusted EBITDA despite adjusting for the iNova and Obagi divestitures. We've also updated key assumptions for expense categories, noncash adjustments and additional cash items, so that you can update your models.

    我們很高興,儘管針對iNova與Obagi剝離進行調整,我們仍能維持調整後EBITDA的指引。我們也更新了費用類別、非現金調整與其他現金項目的關鍵假設,方便各位更新模型。

  • Two quick last things before I turn it back to Joe. In response to feedback we received from many of you, we've changed the format of how we present the impact of the LOE assets on 2017, so that you can see the sales and profits from these products in 2016 and the sales and profits that we expect in 2017, not the change versus '16.

    在我把時間交回給Joe之前,最後快速補充兩點。回應許多各位給我們的回饋,我們改變了呈現LOE資產對2017年影響的格式,讓各位可以看到這些產品在2016年的銷售與利潤,以及我們預期2017年的銷售與利潤,而不是相較於2016年的變動。

  • To be clear, there is no change in the underlying LOE data other than the update to the estimate for the full year 2017. We simply changed the form of how we present the information with the intention of making it more straightforward for you to come to points of view about how both revenues and profits may carry forward beyond 2017.

    為了說清楚,除更新2017全年估計之外,底層的LOE資料沒有任何變動。我們只是改變資訊呈現方式,目的是讓各位更直接地形成觀點,了解營收與利潤在2017年之後可能如何延續。

  • We also added a slide in the appendix to show you the amount of revenue and profits associated with assets divested in 2017 that are expected to be included in our reported 2017 results. This is intended to make it easier for you to isolate those 2017 revenues and profits as you model our go-forward business.

    我們也在附錄新增一張投影片,向各位展示2017年已剝離資產所對應的營收與利潤金額,且預期將納入我們所報告的2017年結果中。此舉旨在讓各位在建立我們未來業務模型時,更容易將這些2017年的營收與利潤單獨拆分出來。

  • With that, I turn it back to you, Joe.

    說到這裡,我把時間交還給你,Joe。

  • Joseph C. Papa - Chairman & CEO

    Joseph C. Papa - Chairman & CEO

  • Thank you, Paul. The chart on Slide 19 has been updated from last quarter to show the progress we've made in closing the previously announced divestitures.

    謝謝你,Paul。第19頁的圖表已從上季更新,以顯示我們在完成先前已宣布之資產剝離方面所取得的進展。

  • As you can see, we have now closed 11 of the 12 previously announced asset sales, and we're expecting to close Obagi very soon. As we transform Valeant, we continue to focus our resources on core businesses because we believe these are the areas where we can best drive value for our shareholders, customers and patients.

    如各位所見,我們目前已完成先前宣布的12項資產出售中的11項,並預期很快就能完成 Obagi 的交易。在我們轉型 Valeant 的同時,我們持續將資源聚焦於核心業務,因為我們相信這些領域最能為股東、客戶與病患創造價值。

  • On Slide 20, third quarter revenues for Bausch + Lomb/International segment were $1.254 billion. The business is growing organically 6%. To me, the chart on the right of the Page 20 says it all for Bausch + Lomb. We've taken a business that was declining to flat a year ago and delivered 3 consecutive quarters of 6% organic growth.

    第20頁顯示,Bausch + Lomb/International 部門第三季營收為12.54億美元。該業務有機成長6%。對我而言,第20頁右側的圖表已充分說明 Bausch + Lomb 的表現。我們把一年前仍在下滑、後來趨於持平的業務,帶到連續三個季度達成6%的有機成長。

  • Bausch + Lomb's presence is also growing on Amazon, with a remarkable 69% growth year-over-year. This is a strong indicator of the strength of the Bausch + Lomb brand.

    Bausch + Lomb 在 Amazon 上的能見度也在提升,年增率高達69%,相當亮眼。這是 Bausch + Lomb 品牌實力的強力指標。

  • Staying with Bausch + Lomb, we provided update on our Consumer and Vision Care business. To call out a few highlights. First, in the international markets, Bausch + Lomb is the #1 Vision Care brand in China, and it's outgrowing the category with a 5-year CAGR of 20%. Our OTC eye drop franchise #is 2 in China, with a strong annual growth rate of 19%.

    延續 Bausch + Lomb 的話題,我們也更新了消費者與視力保健業務。我點出幾個重點。首先,在國際市場方面,Bausch + Lomb 是中國排名第1的視力保健品牌,且以5年複合年成長率(CAGR)20%的速度超越品類成長。我們的OTC眼藥水產品線在中國排名第2,年成長率強勁,達19%。

  • In the U.S., consumer revenues are up 9% organically year-over-year, and the chart in the right shows in the third quarter performance for U.S. Consumer health care companies. While the health and beauty category was down 2.8% in the aggregate, B + L is one of the clear leaders in the category, up 2.5%.

    在美國,消費者業務營收年對年有機成長9%,右側圖表顯示美國消費者健康照護公司的第三季表現。整體健康與美容品類合計下滑2.8%,但 B + L 是該品類中明顯的領先者之一,上升2.5%。

  • On Slide 22, we announced last week that VYZULTA had been approved by the FDA. This is the first novel treatment for patients with glaucoma in over 20 years. VYZULTA is indicative for the reduction of intraocular pressure in patients with open-angle glaucoma. What differentiates VYZULTA is that is the first prostaglandin analog with one of its metabolites being nitric oxide.

    第22頁,我們上週宣布 VYZULTA 已獲 FDA 核准。這是20多年來首個針對青光眼患者的創新療法。VYZULTA 適用於降低開角型青光眼患者的眼內壓。VYZULTA 的差異化在於:它是第一個前列腺素類似物(prostaglandin analog),其代謝物之一為一氧化氮。

  • The efficacy and safety of VYZULTA was evaluated in 2 randomized multicenter studies and also in a Phase 2 versus latanoprost. As the chart on the right demonstrates, latanoprost, or Xalatan's generic equivalent, still account for 2/3 of the market.

    VYZULTA 的療效與安全性在兩項隨機多中心研究中進行評估,並在一項第二期試驗中與拉坦前列素(latanoprost)比較。如右側圖表所示,拉坦前列素(或 Xalatan 的學名藥)仍占市場的三分之二。

  • So why are we excited about VYZULTA? Because globally, glaucoma is a large market opportunity and it's expected to grow at a CAGR of 15% over the next 4-year period. As the first novel treatment in 2 decades, we believe there is great opportunity for VYZULTA.

    那麼我們為何對 VYZULTA 感到興奮?因為在全球範圍內,青光眼是一個龐大的市場機會,且預期未來4年將以15%的複合年成長率成長。作為20年來首個創新療法,我們相信 VYZULTA 具有很大的機會。

  • Moving now to Slide 23 for the update on our Salix business, which generated $452 million of revenue, was up 17% from last quarter and 6% year-over-year excluding divestitures.

    接著看第23頁,更新我們的 Salix 業務:營收為4.52億美元,較上季成長17%,若排除剝離項目,年對年成長6%。

  • A few highlights on XIFAXAN. Revenues sequentially increased 23% from $233 million to $286 million in the quarter, and 5% versus a year ago. XIFAXAN TRx extended units grew by 3% versus third quarter 2016 driven by the IBS-D in Primary Care. And market shares continue to grow, it's up 400 basis points from 73% to 77% since the first quarter of 2017.

    XIFAXAN 的幾個重點。本季營收較前一季由2.33億美元增至2.86億美元,季增23%,且較去年同期成長5%。XIFAXAN 的 TRx 延伸單位數較2016年第三季成長3%,主要由基層醫療(Primary Care)中的 IBS-D 所帶動。市占率持續提升,自2017年第一季以來上升400個基點,從73%提高至77%。

  • Finally, the expanded sales force effort we made in Primary Care contributed to strong growth in TRx volume and new Rx share growth. As you can see from the chart in the upper right, which highlights a 1,300 basis points increase in new Rx share since the addition of the sales force team in Primary Care and February.

    最後,我們在基層醫療擴大銷售團隊的投入,帶動 TRx 量的強勁成長以及新處方(new Rx)市占的提升。如右上方圖表所示,自2月在基層醫療新增銷售團隊以來,新處方市占提高了1,300個基點。

  • Moving on to our other GI promoted brands. RELISTOR prescriptions grew 61% compared to last year. In the lower right-hand corner, you can see how the increased effort from the sales force expansion in Pain and Primary Care is driving RELISTOR oral tablet growth.

    接著談我們其他腸胃道(GI)推廣品牌。RELISTOR 處方量較去年成長61%。在右下角,您可以看到疼痛科與基層醫療擴編銷售團隊後的加大投入,正推動 RELISTOR 口服錠的成長。

  • On to Slide 24. The Ortho Dermalogics business generated $148 million of revenue compared to $130 million last quarter, but was down 34% versus a year ago. Advancing innovative new products to our pipeline will be the key to growing our Dermatology business, and we believe that the products in our pipeline over the next 5 years can double the size of our Dermatology business.

    接著看第24頁。Ortho Dermalogics 業務營收為1.48億美元,較上季的1.30億美元增加,但較去年同期下滑34%。推進創新新產品進入我們的研發管線,將是推動皮膚科業務成長的關鍵;我們相信未來5年管線中的產品可使皮膚科業務規模倍增。

  • The U.S. launch of SILIQ in third quarter demonstrates the strength of our strategy and execution. Early market access is better than expected, and we are continuing to expand and gain additional coverage. Efficacy, durability of efficacy, low induction cost per patient are resonating as key points of differentiation for SILIQ.

    SILIQ 於第三季在美國上市,展現了我們策略與執行力的強度。早期市場准入優於預期,我們也持續擴大並取得更多給付覆蓋。療效、療效持久性,以及每位病患較低的誘導期成本,正成為 SILIQ 的關鍵差異化賣點並引起共鳴。

  • Since the launch, approximately 75% of the patients have been commercially covered by managed care. 98.7% of physicians that have been detailed have agreed to be REMS certified, and there are 371 physicians who've already completed their certification process in the first 2 months.

    自上市以來,約75%的病患已獲商業保險之管理式照護(managed care)覆蓋。接受產品說明(detailed)的醫師中有98.7%同意取得 REMS 認證,且在前兩個月已有371位醫師完成其認證流程。

  • I want to highlight the next potential product in our psoriasis pipeline on Slide #25, IDP-118, an investigational topical treatment for plaque psoriasis. The FDA accepted a New Drug Application for IDP-118 with a PDUFA date of June 18, 2018. If approved, IDP-118 will be the first and only topical lotion that contains a unique combination of halobetasol propionate and tazarotene.

    我想在第25頁重點介紹我們乾癬研發管線中的下一個潛力產品 IDP-118,這是一種用於斑塊型乾癬的研究用外用治療。FDA 已受理 IDP-118 的新藥申請(NDA),其 PDUFA 日期為2018年6月18日。若獲核准,IDP-118 將成為首個且唯一含有獨特組合(鹵倍他索丙酸酯 halobetasol propionate 與他扎羅汀 tazarotene)的外用乳液。

  • Why is IDP-118 important? Existing super-high potency steroids have a 2-week treatment duration limit. In clinical trials, we dosed IDP-118 for up to 1 year. IDP-118 has the potential to be the first high-potency corticosteroid combination for longer-term treatment of psoriasis.

    為什麼 IDP-118 很重要?現有的超高效力類固醇治療通常限制為2週療程。在臨床試驗中,我們對 IDP-118 的給藥最長達1年。IDP-118 有潛力成為首個可用於較長期乾癬治療的高效力皮質類固醇複方。

  • Moving on to Slide 26. We expect 50 new product launches in 2017, including the launch of RELISTOR, SILIQ, the Bausch + Lomb ULTRA and Biotrue ONEday lenses and VYZULTA. I'm delighted to mention another approval recently approved for the Retin-A Micro 0.06% pump, which will be an important line extension in our strong acne franchise. New product launches are expected to generate more than $100 million of annualized revenues in 2017 and, importantly, drive sustainable long-term growth.

    接著看第 26 張投影片。我們預期在 2017 年推出 50 項新產品,包括 RELISTOR、SILIQ、Bausch + Lomb ULTRA 與 Biotrue ONEday 隱形眼鏡,以及 VYZULTA 的上市。我也很高興提到,我們近期又取得一項核准:Retin-A Micro 0.06% 幫浦裝,這將成為我們強勢痤瘡產品線中一項重要的延伸。預期新產品上市在 2017 年可帶來超過 1 億美元的年化營收,且更重要的是,推動可持續的長期成長。

  • On Slide 27, we have an R&D update. As you know, we made significant divestitures over the last 6 to 8 months. As a result, we are refocusing our R&D efforts on those products and businesses that we have identified as core. Therefore, R&D investments for the quarter was lower than expected. That said, as we rotate investment back into the core businesses, we are focused on putting capital into the right projects, which will result in long-term growth opportunities.

    在第 27 張投影片,我們提供研發(R&D)最新進展。如各位所知,過去 6 到 8 個月我們進行了大幅度的資產剝離。因此,我們正將研發資源重新聚焦於我們認定為核心的產品與業務。因此,本季的研發投資低於預期。即便如此,隨著我們把投資重新配置回核心業務,我們專注於將資本投入正確的專案,這將帶來長期的成長機會。

  • On the left side of the page, we review a few of our global R&D catalysts that we will launch in the U.S. and then later introduce globally. On the right, we summarize later-stage R&D pipeline. To call out a few, we have launched 5 new products across our businesses, 2 new contact lenses, 2 surgical vision systems and an innovative biologic treatment for psoriasis.

    在頁面左側,我們回顧幾項全球研發催化劑(catalysts),將先在美國推出,之後再推向全球。右側則摘要較後期階段的研發產品線(pipeline)。舉幾個例子,我們已在各項業務中推出 5 項新產品,包括 2 款新型隱形眼鏡、2 套手術視覺系統,以及一項用於治療乾癬的創新生物製劑療法。

  • The development of new products will drive future growth and enable us to deliver on our mission of improving peoples' lives and delivering total shareholder returns.

    新產品的開發將帶動未來成長,並使我們能實現改善人們生活、並為股東帶來整體報酬的使命。

  • Turning to the next slide, one area that has been critically important for me since I joined the company is delivering on the commitments to our stakeholders. We have taken and will continue to take action that drives shareholder value and benefit to our -- all of our stakeholders. This includes improving operational and commercial excellence, reducing our debt, effectively managing working capital and launching new products.

    接著看下一張投影片,自我加入公司以來,有一個領域對我而言至關重要:兌現對利害關係人的承諾。我們已採取、並將持續採取能提升股東價值、並讓我們——所有利害關係人受益的行動。這包括提升營運與商業卓越、降低負債、有效管理營運資金,以及推出新產品。

  • To date, we have fulfilled our commitments in each of these areas by organically growing 77% of our business by more than 5% in the past 2 quarters; by exceeding our commitment to pay down $5 billion of debt sooner than we expected; by reducing inventory on hand, simplifying our supply chain and discontinuing more than 1,300 SKUs; and finally, by launching new products and advancing promising projects through our pipeline.

    截至目前,我們已在上述各領域履行承諾:在過去兩個季度中,透過內生成長使我們 77% 的業務成長超過 5%;提前且超出我們原先預期地完成償還 50 億美元債務的承諾;透過降低在手庫存、簡化供應鏈並停產超過 1,300 個 SKU;最後,透過推出新產品並推進產品線中具潛力的專案。

  • In conclusion, our strong third quarter results demonstrate that the actions we are taking to move us forward in our efforts to turn the company and transform the (inaudible) several quarters of flat to declining growth. Our largest segment, Bausch + Lomb/International, has been growing 6%. We've built a Primary Care sales force that is driving the growth of the Salix business. Ortho Dermalogics continues to stabilize, and I'm optimistic about the potential pipeline opportunities for acne and psoriasis.

    總結而言,我們強勁的第三季業績顯示,我們正在採取的各項行動正推動公司向前,並在經歷數個季度持平至下滑的成長後,努力扭轉公司並推動轉型(聽不清)。我們最大的事業部門 Bausch + Lomb/International 成長了 6%。我們已建立一支基層醫療(Primary Care)銷售團隊,正帶動 Salix 業務的成長。Ortho Dermalogics 持續趨於穩定,而我對痤瘡與乾癬的潛在產品線機會抱持樂觀。

  • We have taken action to address the quality and efficiency issues at all of our manufacturing sites. We remain committed to investing in innovation as the foundation of our future growth. And finally, we will continue to hold ourselves accountable for delivering on our promises to better serve our customers, employees and shareholders.

    我們已採取行動,解決所有製造據點的品質與效率問題。我們仍致力於投資創新,將其作為未來成長的基礎。最後,我們將持續要求自己對兌現承諾負責,以更好地服務客戶、員工與股東。

  • With that, operator, let's open up the line for questions.

    接下來,接線員,請開放電話線讓大家提問。

  • Operator

    Operator

  • (Operator Instructions) Your first question comes from the line of Umer Raffat with Evercore ISI.

    (接線員指示) 第一個問題來自 Evercore ISI 的 Umer Raffat。

  • Umer Raffat - Senior MD and Fundamental Research Analyst

    Umer Raffat - Senior MD and Fundamental Research Analyst

  • I wanted to focus on 2 topics, if I may. First, just on Bausch + Lomb. I was looking at the organic growth estimates, and one of the questions I had was how much of the year-over-year growth is coming from the channel refill in Eastern Europe? Just wanted to understand and quantify that, if I may. And just to put it in the context of 6% year-over-year growth reported for the Bausch segment. So this is, again, from the Eastern European and international channel refill. And the second one is maybe for Paul. Paul, can you help us understand exactly what the year-over-year -- so if I just take the latest quarter's EBITDA, annualize it, how much of a year-over-year, like going into 2018, LOE impact would you guide that to? Because I see that slide you guys put up in the appendix, and I just want to make sure I fully understand what's -- what you guys are baking in versus not.

    如果可以的話,我想聚焦在兩個主題。第一個是關於 Bausch + Lomb。我在看內生成長的估計時,有個問題是:年對年成長中,有多少是來自東歐通路補貨(channel refill)?如果可以的話,我想了解並量化這一點。並且把它放在 Bausch 部門所報告的 6% 年對年成長的脈絡下。所以這部分再次是來自東歐與國際通路補貨。第二個問題可能是給 Paul。Paul,你能否協助我們精確理解年對年——也就是如果我把最新一季的 EBITDA 年化,針對進入 2018 年的 LOE 影響,你會給出多少年對年的指引?因為我看到你們在附錄放的那張投影片,我只是想確認我完全理解你們已納入(baking in)與未納入的內容。

  • Joseph C. Papa - Chairman & CEO

    Joseph C. Papa - Chairman & CEO

  • Umer, I'll take the first part of the question. And then, Paul, I'll turn it to you for that second part of the question. Well, I mean, first of all, if you think about what's happening with Bausch + Lomb, you can see that all of the businesses, with the exception of the Ophtho Rx, are growing organically. So we have the Global Vision Care at plus 8% organically, there's Global Surgical at plus 2%, the Global Consumer at plus 6%. Those together account for a fairly large part of the, let's call it, more than the 50%, 60% of our total business in the Bausch + Lomb/International segment. So that's clearly the largest part of the business. There is some significant international revenue growth, and I think as Paul said that the restocking of Poland did help that international business. But we also got some significant price appreciation in Egypt as a result of the some of the currency devaluation that has occurred previously. So I think it's been a combination of factors. I don't have the specific impact of the international side, but I would say a large part of that international growth, going from the $327 million to the $344 million, or let's call it the $17 million, a large part of that is result of some of the restocking but also the Egyptian currency devaluation and the price increases there. That's really the majority of that portion. But you can really quickly -- because of the way we've done it, you can really look at it by each of the individuals. We give you exactly the sales numbers and the actual growth rates. So it gives you a chance to break it out, to answer exactly the questions. I just don't want to give you the math as I'm sitting here right now.

    Umer,我先回答問題的第一部分。然後第二部分我再交給 Paul。首先,如果你看 Bausch + Lomb 的情況,你會看到除了 Ophtho Rx 之外,所有業務都在內生成長。因此,我們的全球視力保健(Global Vision Care)內生成長為 +8%,全球手術(Global Surgical)為 +2%,全球消費(Global Consumer)為 +6%。這些合計占 Bausch + Lomb/International 部門總業務相當大的一部分,我們姑且稱之為超過 50%、60%。所以這顯然是業務中最大的一塊。國際營收確實有顯著成長,而且如 Paul 所說,波蘭的補庫存確實對國際業務有所幫助。但同時,由於先前發生的一些貨幣貶值,我們也在埃及取得了顯著的價格提升。所以我認為這是多種因素的組合。我沒有國際端具體影響的精確數字,但我會說,國際業務從 3.27 億美元到 3.44 億美元的成長(約 1,700 萬美元),其中很大一部分來自補庫存,同時也包括埃及貨幣貶值以及當地的提價。那基本上就是該部分的大多數原因。不過你其實可以很快——因為我們呈現的方式——按各個項目來看。我們會提供你精確的銷售數字與實際成長率。因此你有機會把它拆開來看,以精確回答這些問題。我只是不想在我現在坐在這裡的情況下,直接把數學計算結果報給你。

  • Paul S. Herendeen - EVP of Finance & CFO

    Paul S. Herendeen - EVP of Finance & CFO

  • Umer, it's Paul. I can do the math because I have those kind of worksheets in front of me all the time. About 30% of the volume pickup in B + L/International was related to the pipeline activity. So 70% of it came -- 70% of the volume pickup in international came from other than the pipeline. Surely, we benefited from it. That's why I called it out in my remarks. Second -- the second question you had was how do you think about using the revised presentation of the LOE assets. And what I would say is now we're showing that, that basket of LOE assets -- very specific baskets, like the products included in that basket, have not changed. We expect to have sales in our 2017 results totaling approximately $524 million in profit, which I don't have that slide right in front of me right now, but the associated profit. It won't go away in its entirety in 2018. We're also not providing guidance today on 2018, but that's certainly -- a solid portion of that will carry forward into 2018 and potentially beyond. I mean, while they're LOE assets, they won't go to 0. They may asymptotically approach 0, but they won't go to 0. I hope that answers. And if it doesn't, I'll hopefully see you at lunch later, we can talk more.

    Umer,我是 Paul。我可以算得出來,因為我一直都有這類工作表放在眼前。B + L/國際業務的出貨量提升中,大約 30% 與管線(pipeline)活動有關。所以其中 70%——國際業務出貨量提升的 70%——來自非管線因素。我們當然也從中受益。這就是我在發言中特別點出的原因。第二——你第二個問題是,如何看待以修訂後的方式呈現 LOE 資產。我想說的是,現在我們呈現的是,那一籃 LOE 資產——非常特定的組合,例如該組合所包含的產品——並沒有改變。我們預期在 2017 年的實際結果中,來自相關銷售的利潤合計約為 5.24 億美元;我現在手邊沒有那張投影片,但就是對應的利潤。它不會在 2018 年完全消失。我們今天也不提供 2018 年的指引,但可以肯定的是——其中相當一部分會延續到 2018 年,甚至可能更久。我的意思是,雖然它們是 LOE 資產,但不會降到 0。它們可能會漸近於 0,但不會變成 0。希望這回答了你的問題。如果還沒有,我希望稍後午餐時能見到你,我們可以再多聊。

  • Operator

    Operator

  • Your next question comes from Gregg Gilbert with Deutsche Bank.

    下一個問題來自德意志銀行(Deutsche Bank)的 Gregg Gilbert。

  • Gregory B. Gilbert - MD and Senior Analyst

    Gregory B. Gilbert - MD and Senior Analyst

  • Paul, I know you're not looking to give guidance for 2018, but can you offer any observations as you consider how people are modeling it and things you'd like to point out now to avoid any confusion as we head into '18? And maybe kind of offer some preliminary thoughts on the items in tax reform that you have an eye on that could be issues for Valeant.

    Paul,我知道你不打算提供 2018 年的指引,但在你思考大家如何建模(modeling)以及你希望現在先指出哪些事項以避免我們進入 2018 年時產生混淆方面,你能否提供一些觀察?另外,也許可以先談談你正在關注、可能會對 Valeant 造成影響的稅改項目。

  • Paul S. Herendeen - EVP of Finance & CFO

    Paul S. Herendeen - EVP of Finance & CFO

  • Yes, sure. I mean, let me address first thinking about '18. Obviously, as I said, we're not providing guidance for '18. That said, I mean, in the spirit of transparency, and as I said, we're being responsive to feedback that we got from number of investors, we've added -- I've added, and we changed the presentation of that LOE slide and we've added a slide to show you exactly the -- exactly, the estimates of what we expect revenue and profits will be from divested assets included in our actual 2017 results. And so using your own estimate of 2017, you should be able to pull apart and get rid of the divested assets. And then as Umer was -- the road Umer was going down, come to your own points of view about how to think about that basket of the 2017 LOE products, how that $524 million translates into 2018 and, as I said, potentially beyond. So the pieces are all there, but I'll give you one qualitative point, which I'm very comfortable making the statement is, to set aside the LOE assets, set aside all the divested assets, we are confident that the base business, the business that we manage, the business that we can control and manage and drive fundamentals for, will grow in '18 v. '17. That's our core businesses. And so that, I hope, provides at least a framework for how you might think about 2018. The tax reform thing like, gee, it came out last week. And while there's a lot there, in the proposal obviously contains several provisions that could impact on our go-forward tax rate. And before I get into those 3 areas, I'll just point out none of this is final. And all companies, including us, are guessing at this stage how it might impact our situations. You've heard me say in the past I think one of the best features of our global structure is our flexibility, and it affords us the ability to respond to changing environments. So that's good news, and we will need that flexibility depending on how this shakes out. With respect to the proposal, there were 3 major areas that could impact us, and I'll list them kind of in order of potential magnitude. The first is the proposal contains a 20% excise tax on payments made by U.S. entities to related foreign companies. If this is enacted just that way, this is going to be a problem not just for us, but for any multinational companies, U.S. or otherwise, that do business in the U.S. and have manufacturing and intellectual property located outside the U.S. That one's going to be one that we're going to need to work on. And by the way, that's not -- it's not known how that'll sort out. I think there was a Chairman's amendment as recently as yesterday that further modified the proposal. So we're all scrambling to try to understand that as well. The second thing that I'd point out is it also contains a mechanism for taxing unrepatriated foreign earnings of U.S. entities. Now while we are a Canadian company, we do have U.S. entities and we do have entities that are below that U.S. entity, where we do have some repatriation issues. I'll say that, ultimately, this is not going to be an enormous amount of -- depending on how it plays out, an enormous impact on us, but it's not 0 either. It will result in incremental tax to us, not reported in our GAAP tax rate, but it will be cash that would be paid. Not of a great magnitude. I think the current proposal, that could be paid over 8 years and so not that big a deal. And the last part of the proposal that could impact us would be the limits placed on the deductibility of interest on intercompany debt by U.S. entities. Again, I'm just going to say it's very, very early days here. And what the final legislation might look like when it comes out of the House is anybody's guess. But based on what's proposed now, the 20% excise tax would present our biggest challenge. And I'm certainly glad that we have a flexible structure that will enable us to do the things that we can do to appropriately manage our overall global tax rate.

    好的,當然。我先談談對 2018 年的思考。很明顯,如我所說,我們不提供 2018 年的指引。不過,本著透明化精神,也如我所說,我們在回應多位投資人給我們的回饋,我們已經——我已經——調整了 LOE 那張投影片的呈現方式,並新增一張投影片,讓你清楚看到——清楚地——我們預期在 2017 年實際結果中,納入已剝離資產後的營收與利潤估計。因此,使用你自己對 2017 年的估計,你應該能把已剝離資產拆分出來並排除。接著,如同 Umer 剛才——Umer 正在走的那條思路——你可以形成你自己的觀點,來思考 2017 年那一籃 LOE 產品,以及那 5.24 億美元如何轉換到 2018 年,並且如我所說,可能延伸到更久之後。所以所有拼圖都在那裡;但我會給你一個我很有把握提出的定性觀點:先把 LOE 資產放一邊、把所有已剝離資產放一邊,我們有信心,基礎業務——也就是我們管理的業務、我們能控制並管理、並能推動基本面(fundamentals)的業務——在 2018 年相較 2017 年會成長。那就是我們的核心業務。因此,我希望這至少能提供一個你思考 2018 年的框架。至於稅改,像是,嗯,它是上週才出來的。雖然內容很多,但該提案顯然包含數項條款,可能影響我們未來的有效稅率。在我談那 3 個領域之前,我先指出,這些都還不是定案。所有公司,包括我們在內,現階段都只能推測它可能如何影響各自情況。你過去聽我說過,我認為我們全球架構最好的特點之一就是彈性,它讓我們有能力因應環境變化。這是好消息,而我們也會需要這種彈性,視最終結果而定。就該提案而言,有 3 個主要領域可能影響我們,我會大致按可能影響幅度由大到小列出。第一,提案包含對美國實體支付給關聯海外公司的款項課徵 20% 的消費稅(excise tax)。如果就以這種方式立法通過,這不只會是我們的問題,也會是任何跨國公司——不論是美國或非美國——只要在美國營運、且製造與智慧財產權位於美國境外,都會面臨的問題。這一項我們需要著手處理。順帶一提,這會如何落地目前也不清楚。我想就在昨天,主席修正案(Chairman's amendment)還進一步修改了提案。所以我們也都在趕著理解那部分。第二點我想指出的是,它也包含一套機制,對美國實體未匯回(unrepatriated)的海外盈餘課稅。雖然我們是一家加拿大公司,但我們確實有美國實體,也有位於該美國實體之下的其他實體,因此確實存在一些匯回(repatriation)議題。我會說,最終而言,視其如何落地,這對我們不會造成非常巨大的影響,但也不是 0。它會使我們產生額外稅負,不會反映在我們的 GAAP 有效稅率中,但會是需要支付的現金。金額不會很大。我認為依目前提案,這筆款項可分 8 年支付,因此影響不算大。而提案最後一個可能影響我們的部分,是對美國實體就公司間債務(intercompany debt)利息可扣抵性所施加的限制。同樣地,我只能說現在還非常早期。最終從眾議院出來的法案會長什麼樣,誰也說不準。但就目前提案而言,20% 的消費稅將是我們最大的挑戰。而我也很慶幸我們有一個具彈性的架構,能讓我們採取必要作為,以妥善管理我們整體的全球有效稅率。

  • Joseph C. Papa - Chairman & CEO

    Joseph C. Papa - Chairman & CEO

  • The only comment I'd add to what Paul said, Gregg, is I think, clearly, we're not going to provide 2018 guidance. But the key variables for us and for all pharmaceutical and health care companies has always been come back to the new products. Fortunately, we've got a number of over 50 launches in 2017 in new products, products including RELISTOR, SILIQ, VYZULTA, the RAM or Retin-A Micro 0.06%, Stellaris Elite, Vitesse, the Ultra Toric multifocal. And then rolling into 2018, we're going to have products like the IDP-118 if approved, PLENVU if approved, Si-Hy daily, Luminesse if approved. So we've got a number of good opportunities for the new product side as we think about 2018, and I think that's going to be an important driver for us.

    我對 Paul 所說的唯一補充,Gregg,是我認為很明顯,我們不會提供 2018 年的財測指引。但對我們以及所有製藥與醫療保健公司而言,關鍵變數一直都是回到新產品。所幸的是,我們在 2017 年有超過 50 項新產品上市,包括 RELISTOR、SILIQ、VYZULTA、RAM 或 Retin-A Micro 0.06%、Stellaris Elite、Vitesse、Ultra Toric 多焦點。接著進入 2018 年,我們將有像是 IDP-118(若獲核准)、PLENVU(若獲核准)、Si-Hy daily、Luminesse(若獲核准)等產品。因此,當我們思考 2018 年時,在新產品面向我們有多個良好機會,而我認為這將會是我們的重要驅動因素。

  • Operator

    Operator

  • Your next question comes from Louise Chen of Cantor.

    下一個問題來自 Cantor 的 Louise Chen。

  • Louise Alesandra Chen - Senior Research Analyst & MD

    Louise Alesandra Chen - Senior Research Analyst & MD

  • So I'm just curious, what gives you confidence that you can enhance equity shareholder value given the large amount of debt that you have to pay down? And what are some of the key growth drivers that you feel good about right now as the base business actually is stabilizing? And then are you still considering creative ways to lower your leverage ratio?

    我只是好奇,在你們有大量債務需要償還的情況下,是什麼讓你們有信心能提升股東權益價值?另外,當基礎業務實際上正在趨於穩定時,你們目前看好的一些關鍵成長驅動因素是什麼?還有,你們是否仍在考慮以更具創意的方式來降低槓桿比率?

  • Joseph C. Papa - Chairman & CEO

    Joseph C. Papa - Chairman & CEO

  • Well, let me start. And then I think, first and foremost, what we've done since I arrived and since Paul has arrived is really focus our attention towards what are the key growth drivers for this business, which in the health care is always going to come out with new products. So we continue to look at these new products, introduce new products, get new products through the pipeline. As I said, we're really excited about product -- a product like VYZULTA. If you look at what -- the market today for glaucoma, it's a large market. It's a growing market. And the reality is that 2/3 of the market in the U.S. at least is either a Xalatan or a generic equivalent to Xalatan. We have a dual mechanism of action that includes the latanoprostene, but also has the nitric oxide donation. That dual action is really what we think is going to be important. If we go through -- the same comments for IDP-118. The facts are that the current treatment of psoriasis were the topical products, but the super-high potency steroid are limited to a 2-week duration because of the potential effects on the thinning or attribute of the skin. We believe that based on what we've submitted to the FDA, if approved, this could be a game-changer with IDP-118 because of the ability to use it for a longer duration. Those are the types of reasons why we think that we've got a very strong business and good, strong growth opportunities. Clearly, we're seeing the results with XIFAXAN in our incremental promotion efforts. So we put those forward as ways that we could help drive the bottom line of our business, increase our EBITDA. And as that EBITDA comes forward, reduce our debt. Final comment I'd say is if you look at what Paul and Linda have done in terms of moving out the debt, we've done a lot to take the debt, push it out further. So there's no debt due between now and 2020. That gives us the, what I call, freedom to operate to ensure that, over the long term, we can drive shareholder value for the future. So to me, that's really the game plan. Grow the base business, launching new products and then, obviously, take the bottom line, look at the improvements we made in working capital and put that towards debt reduction, which makes us a stronger company for the future.

    好,我先開始回答。我認為,首先也是最重要的是,自從我到任以及 Paul 到任以來,我們真正做的是把注意力聚焦在這項業務的關鍵成長驅動因素是什麼;而在醫療保健領域,這永遠會回到推出新產品。因此,我們持續檢視這些新產品、導入新產品,並推動新產品通過研發管線。如我所說,我們對像 VYZULTA 這樣的產品感到非常振奮。如果你看目前青光眼的市場,它是一個很大的市場。它也是一個成長中的市場。而現實是,至少在美國,市場中有 2/3 是 Xalatan 或其學名藥等同品。我們具有雙重作用機制,包含 latanoprostene,同時也具有一氧化氮供體作用。我們認為這種雙重作用將非常重要。同樣的評論也適用於 IDP-118。事實是,目前乾癬的治療是外用產品,但超高效力類固醇因可能造成皮膚變薄或皮膚特性改變的影響,而被限制只能使用 2 週。我們相信,根據我們提交給 FDA 的資料,若獲核准,IDP-118 可能會因可使用更長療程而成為改變遊戲規則的產品。這些就是我們認為我們擁有非常強健的業務與良好、強勁成長機會的原因。很明顯地,我們在 XIFAXAN 的增量推廣努力上已看到成果。因此,我們提出這些作為能協助推動公司獲利、提升 EBITDA 的方式。而隨著 EBITDA 提升,我們就能降低負債。最後我想說的是,如果你看 Paul 和 Linda 在延後到期債務方面所做的事,我們已做了很多,把債務到期日往後推。因此,從現在到 2020 年之間沒有到期債務。這讓我們擁有我所稱的「營運自由度」,以確保長期而言我們能為未來創造股東價值。所以對我來說,這就是整體作戰計畫。成長基礎業務、推出新產品,然後,當然,把獲利端的成果,以及我們在營運資金上所做的改善,用於減債,讓我們成為一家更強健、面向未來的公司。

  • Operator

    Operator

  • Our next question comes from Annabel Samimy of Stifel.

    下一個問題來自 Stifel 的 Annabel Samimy。

  • Andrew Abriol Santos Ang - Associate

    Andrew Abriol Santos Ang - Associate

  • This is Andrew in for Annabel. So my question is so SILIQ appears to be getting strong reimbursement and good feedback, but we're still seeing an extremely competitive environment in psoriasis with some competing products. Specifically, (inaudible) rebate pressure. When we think about next year, can SILIQ offset the declines in Derm and expected LOEs by next year? Or do we have to wait until 2019 when other products are on board? And if I could squeeze in another one. Your near-term debt goals have been met and you still have strong cash flow. So can you be more constructive on capital allocation now that you refocus on -- to refocus on operational investment or business development? Or are you still more focused on balance sheet strengthening? And do you have a plan -- do you have another debt pay-down target?

    我是 Andrew,代 Annabel 提問。我的問題是,SILIQ 似乎獲得強勁的給付/報銷支持與良好回饋,但我們仍看到乾癬領域競爭極為激烈,且有一些競品。特別是,(聽不清)回扣壓力。當我們思考明年時,SILIQ 能否在明年抵消皮膚科業務下滑以及預期的專利到期(LOE)影響?還是我們必須等到 2019 年、當其他產品到位後才行?如果我可以再塞一個問題。你們的短期減債目標已達成,而且仍有強勁的現金流。因此,在你們重新聚焦於——重新聚焦於營運投資或業務開發之際,你們能否對資本配置更具建設性一些?或者你們仍更專注於強化資產負債表?以及你們是否有計畫——是否有下一個減債目標?

  • Joseph C. Papa - Chairman & CEO

    Joseph C. Papa - Chairman & CEO

  • Okay, well, I'll take the first one, and then, Paul, you take the second one. Let me start with we're very pleased with SILIQ. We knew that the update for SILIQ was going to be slow in the sense that, well, we knew that we had to put physicians, get them through a REMS certification. We're doing that as we speak. And as I said, we have over 371 physicians already REMS certified. We think that's an important first step. We are seeing patients in terms of -- as they enroll. We're seeing the usage of product. We think the important comment about SILIQ is that the long-term value of it is really going to be in the rapid onset of efficacy with the product and then the long duration of efficacy. Because once again, we are the receptor blocker versus the other products that inhibits the enzymatic pathway around the inflammatory factors. We block the receptor. We think that's what's good for the long term. The only other comment I would say on 2018 is, clearly, the other areas that we are looking for growth in the Dermatology business is the IDP-118, first and foremost is being approved -- or has a PDUFA date in June 18, 2018. We think that would be potentially a contributor to our long-term growth of the Dermatology business, especially based on the comments I made before in terms of it being a unique product potentially with the opportunity to use longer duration of therapy than previous high-potency corticosteroids. And then obviously, we have the Retin-A Micro 0.06% as another way to strengthen our acne. So we think it's the combination of all those activities that are really going to help us to grow the Dermatology business. And importantly, as I said before, we have enough products in our pipeline over the next 5 years that we believe double the size of the business based on where it is today. Paul, you want to talk about the capital allocation?

    好的,我先回答第一個,然後 Paul 你回答第二個。先說我們對 SILIQ 非常滿意。我們知道 SILIQ 的導入會比較慢,因為——我們知道我們必須讓醫師完成 REMS 認證。我們正在進行中。如我所說,目前已有超過 371 位醫師完成 REMS 認證。我們認為這是重要的第一步。我們也看到病患在——在他們加入/註冊時。我們看到產品的使用情況。我們認為 SILIQ 的重要之處在於,其長期價值將主要來自於起效迅速,以及療效維持時間長。因為再一次,我們是受體阻斷劑,而其他產品是抑制與發炎因子相關的酵素途徑。我們阻斷的是受體。我們認為這對長期而言是有利的。關於 2018 年我唯一想再補充的是,很明顯地,我們在皮膚科業務中尋求成長的其他領域,首先是 IDP-118,若獲核准——其 PDUFA 日期是 2018 年 6 月 18 日。我們認為這可能會對皮膚科業務的長期成長有所貢獻,特別是基於我先前提到的,它可能是一個獨特的產品,並有機會使用比以往高效力皮質類固醇更長的治療期間。然後很明顯地,我們還有 Retin-A Micro 0.06% 作為強化痤瘡產品線的另一種方式。因此,我們認為上述所有活動的組合,將真正幫助我們成長皮膚科業務。而且重要的是,如我先前所說,我們在未來 5 年的研發管線中有足夠的產品,我們相信可在目前基礎上把業務規模擴大一倍。Paul,你要談談資本配置嗎?

  • Paul S. Herendeen - EVP of Finance & CFO

    Paul S. Herendeen - EVP of Finance & CFO

  • Sure. If I may, I may just spend 2 seconds on the Derm as well. Because I think that, one, we have the opportunity to deal -- we have a very attractive legacy portfolio. We watched it, obviously, face a very difficult reimbursement environment as I said in my prepared remarks. I mean, we've seen stabilization of our realized net pricing. And now that becomes a volume game. And it becomes a game where, over a period of time, we would expect to maximize the value of that legacy portfolio. We're not just turning away from it. I think there's real value there. And as Joe said then you lay on top of that in -- looking ahead to '18, again, not providing guidance but stating that we've got SILIQ, you've got IDP-118, you've got RAM 0.06%. I mean, we've got a number of new products that we would expect to help us turn that franchise back to a growth mode, and we think we have great opportunity with Ortho Dermatologics. On the balance sheet, you hit it, Andrew. You hit on a topic that's very challenging going forward. As I said at all times, is -- first, if you had a list of 5 priorities, the first 4 are generate cash to reduce debt. That's top of our mind for sure. That said, we do come across some modest, and I -- emphasis on modest or even call them small-sized opportunities to use capital to acquire rights, to lay things into our R&D pipeline and all. And so to the extent that we see those things, we're likely to pursue them if they make sense. And I think that you should be encouraged as either debt or equity investors that as we think about deploying that capital to those sorts of activities, we have a very tight screen. We have to. We have a priority of reducing our indebtedness. We're not going to establish a new debt pay-down structure, and kind of responding to both yours and a bit to Louise's question as well, is we feel like a year ago, it was mandatory that we pursue divestitures in order to be able to reduce the quantum of that debt and make progress against reducing the quantum of debt. Sitting here today, I think we think of our go-forward position on future divestitures for pay-down as being more in the opportunistic category. We don't have to. However, we do have a well-defined point of view with respect to the value of each and every one of our business units. And to the extent that someone picked up that phone and called us and said, gee, I want to own that asset, and that we think that asset is worth 100 and they say they're willing to pay 120, we're going to entertain that and probably sell that asset. But it is more opportunistic than, I would say, a year ago when it was pretty much mandatory that we pursue the divestiture of a number of assets.

    好的。如果可以的話,我也想再花 2 秒談一下皮膚科(Derm)。因為我認為,第一,我們有機會去處理——我們擁有一個非常具吸引力的既有產品組合(legacy portfolio)。如同我在事先準備的講稿中所說,我們也看到它顯然面臨非常艱難的給付/報銷環境。我的意思是,我們已經看到已實現的淨價格趨於穩定。而現在這就變成一個量的遊戲。並且在一段時間內,這會是一個我們預期能將該既有產品組合價值最大化的遊戲。我們並不是要放棄它。我認為那裡面確實有價值。而且如同 Joe 所說,接著你再把它疊加上——展望 2018 年,再次強調不是提供指引,而是陳述我們有 SILIQ、有 IDP-118、有 RAM 0.06%。我的意思是,我們有多個新產品,我們預期能幫助我們讓該事業群回到成長模式,我們也認為 Ortho Dermatologics 有很大的機會。至於資產負債表,你說到重點了,Andrew。你提到了一個未來非常具挑戰性的議題。如同我一直說的——首先,如果你列出 5 個優先事項,前 4 個都是:產生現金以降低負債。這當然是我們最關注的事。話雖如此,我們確實會遇到一些不大的——我強調是不大,甚至可以說是小型的——運用資本去取得權利、把項目放進我們的研發管線等機會。因此,只要我們看到這些事情,而且合理,我們很可能會去做。我也認為,無論你是債權或股權投資人,都應該感到放心:當我們考慮把資本部署到這類活動時,我們有非常嚴格的篩選標準。我們必須如此。我們的優先事項是降低負債。我們不會建立新的還債架構;同時回應你以及也部分回應 Louise 的問題:我們覺得在一年前,為了能降低那筆債務的規模並在降低債務規模上取得進展,進行資產剝離是必須的。而今天坐在這裡,我想我們對於未來為了還債而進行的資產剝離,更偏向機會型(opportunistic)。我們不一定非做不可。不過,我們對於每一個事業單位的價值都有非常明確的觀點。如果有人拿起電話打給我們說:「我想擁有那項資產」,而我們認為那項資產值 100、對方願意付 120,我們會考慮,並且很可能會出售那項資產。但我會說,這比起一年前(當時幾乎是必須推動多項資產剝離)更偏向機會型。

  • Operator

    Operator

  • Your next question comes from David Amsellem of Piper Jaffray.

    下一個問題來自 Piper Jaffray 的 David Amsellem。

  • David A. Amsellem - MD and Senior Research Analyst

    David A. Amsellem - MD and Senior Research Analyst

  • So I got a couple of XIFAXAN questions. So I realize that the NRx share has grown based on the chart in Slide 23. But it does look like overall volumes year-over-year are kind of stuck in the single-digit range. So do you feel that you're getting enough out of the Primary Care sales force? And then secondly, what are your expectations for 2018? Do you still think that you can get an uptick in sales? Or are we looking at more of a maturing type of landscape for XIFAXAN? And then lastly, in terms of gross-to-nets, maybe give us some color on what you think 2018 might be for the product as well?

    我有幾個關於 XIFAXAN 的問題。我知道根據第 23 張投影片的圖表,NRx 市占率已經成長。但看起來整體用量年對年似乎卡在個位數區間。所以你覺得你們從基層醫療(Primary Care)銷售團隊那邊獲得的成效夠嗎?第二,你們對 2018 年的預期是什麼?你們仍然認為銷售可以出現回升嗎?還是我們看到的是 XIFAXAN 逐漸成熟的市場態勢?最後,關於 gross-to-nets(毛額到淨額折讓),也請你們談談對 2018 年這個產品可能會是什麼情況。

  • Joseph C. Papa - Chairman & CEO

    Joseph C. Papa - Chairman & CEO

  • Okay. I'll start and I hope I get all the pieces that you said. So first and foremost, as I said, we think we're going to get single -- we've been at single-digit growth in the business in terms of what we've seen historically. I think what we've tried to do, and looking at Primary Care though, is really open up for a very large opportunity as it would relate to the IBS-D category. We're seeing in IBS-D an opportunity to grow -- significantly grow our share in that category, and we've not yet saturated that market anything close to it. We think there's a lot more opportunity there in IBS-D. When we looked at the Primary Care team we put together, it was 200-plus sales professionals. We looked at it from a return on investment point of view, and we're going to always continue to look at it that way. We're pleased with the results we're seeing already. Obviously, the teams got to continue to develop. They've only been out there as of the date that we presented really for about 8 months. So we think we're still in the early stages of the success of that. We think that will continue to accelerate for 2018 and beyond. So that brings me to that part of the question. Where do we see growth in 2018 and beyond? We think there is an opportunity to have a growth in volume. We're not going to give guidance specifically now, but we think that the volume will go up. We also think that there is an opportunity to have, what I'd call, a single-digit price increase, which, in my mind, if I use 8% just for the sake of argument, I'm not saying we're going to be increase prices 8%, we'd get about 4% pricing. In other words, we get about half of what we put forward as a gross price as a net realized price is the logic we have. We're not, once again, saying what prices will do next year. On the comment on gross-to-nets, my comment on gross-to-net is there will always be additional pressure on gross-to-net. We're somewhere -- in the GI category, somewhere in that 40% gross-to-net. Do I believe it's somewhere around that next year? The answer is yes. It's been relatively consistent. We -- in the time I've been with the business, 2016, 2017 is approximately that 40% gross-to-net. I expect it to be relatively consistent with that going into 2018 and beyond as well.

    好的。我先回答,我希望我能把你提到的各個部分都涵蓋到。首先,如同我說的,從我們過去的歷史來看,我們認為這項業務一直是個位數成長——我們也一直看到是個位數成長。我想我們嘗試做的事情,特別是從基層醫療的角度,是針對 IBS-D 類別真正打開一個非常大的機會。我們在 IBS-D 看到有機會——在該類別中大幅提升我們的市占率,而且我們距離把那個市場做到飽和還差得很遠,甚至完全談不上接近飽和。我們認為在 IBS-D 還有更多機會。當我們組建基層醫療團隊時,規模是 200 多位銷售專業人員。我們是從投資報酬(ROI)的角度來評估,而且我們會一直用這個方式持續檢視。我們對目前已經看到的成果感到滿意。當然,團隊還需要持續成長與成熟。截至我們簡報的時間點,他們實際在外推動大約只有 8 個月。所以我們認為這項成功仍在早期階段。我們認為在 2018 年及之後,這會持續加速。這就帶到你問題的那一部分。那麼,我們在 2018 年及之後看到的成長在哪裡?我們認為用量有機會成長。我們現在不會提供具體指引,但我們認為用量會上升。我們也認為有機會出現我所稱的個位數價格上調;以我自己的想法,如果只是為了舉例用 8% 來說——我不是說我們會漲價 8%——我們大概能得到約 4% 的價格貢獻。換句話說,我們的邏輯是:我們提出的毛價(gross price)大約只有一半會反映為實現的淨價格(net realized price)。我們再次強調,並不是在說明明年的價格會怎麼走。至於 gross-to-nets 的評論,我的看法是:gross-to-net 永遠都會面臨額外的壓力。我們在 GI 類別大概是在 40% 左右的 gross-to-net。我是否相信明年也會大致在那個水準?答案是會。它一直相對一致。在我加入這項業務以來,2016、2017 年大約都是 40% 的 gross-to-net。我預期進入 2018 年以及之後,也會與此大致一致。

  • Operator

    Operator

  • Your next question comes from Dave Risinger of Morgan Stanley.

    您的下一個問題來自摩根士丹利(Morgan Stanley)的 Dave Risinger。

  • David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst

    David Reed Risinger - MD in Equity Research and United States Pharmaceuticals Analyst

  • In terms of questions, so first, could you just talk about fill rates? How you're experiencing fill rates in the U.S., whether there are any changes. We're hearing from some other companies that they are experiencing some fill rate pressure. Second, could you just update us on your focus on resolving litigation issues and, I don't know, key areas to watch in the near term? And then third, if you could discuss cost-cutting opportunities ahead. I'm not clear on where you are in rationalizing the cost structure.

    就問題而言,首先,您能否談談處方配藥完成率(fill rates)?您們在美國所觀察到的配藥完成率情況如何,是否有任何變化。我們從其他一些公司聽說,他們正面臨一些配藥完成率的壓力。第二,您能否向我們更新一下您們在解決訴訟問題方面的重點,以及我不知道,短期內有哪些需要關注的關鍵領域?第三,如果可以的話,請談談未來的成本削減機會。我不太清楚您們在精簡成本結構方面進展到哪一步。

  • Joseph C. Papa - Chairman & CEO

    Joseph C. Papa - Chairman & CEO

  • Sure. So I will say on this question of fill rates and what we're seeing in our -- the people picking up our prescriptions, we do have the data. We are looking at -- what I'd refer to all of that is really compliance and how patients are filling their prescriptions. We check that, especially in all of our chronic medications, XIFAXAN for example. We have put together a number of programs where we think we're trying to put programs in place that improves the patients' compliance. Those types of programs that -- especially as you do them with specialty pharmacies like we do with SILIQ, are all designed to try to help patients and make sure that we improve that. But we -- it is something we're keeping our mind on. We're not seeing a lot of challenges there, but it is something we're keeping a look on all the time, David. On the question of resolving litigation, what can I -- I don't know if I can say much more than what we've done in the presentation. Christina Ackermann and her legal team have just done an outstanding job. If you think about from the second quarter earnings call to now, resolving 21 litigation or legal matters we think is an outstanding achievement and very much credit to the team that's done that as we've worked our way through it. The issues that we've identified, I mean, each one of them are in the slides, I think are all very important matters for us. I mean, if you think about the -- we had a GLUMETZA case that got identified. We've been working with them. For some reason, they filed a lawsuit. We did solve that though very quickly, got it behind us and that's really the important way that we're approaching it. Where we can get these resolved, we're going to get them resolved, move forward with all of our litigations. But obviously, defending our cases rigorously where we believe we have the right answers and we're going to do that, and that's whether it's any kind of litigation or intellectual property. On the last part of your question on cost-cutting, we've done a lot. We've taken out operating expense nearly $100 million from 2016, 2017. As we look at the divested assets that we have in 2017, we're going to continue to look at where can we reduce the operating expenses of the company to make sure that we put it towards, what I've referred to before, the core business. Places where we think we have the best return on investment for our growth is really we're going to focus on for our cost-cutting. Obviously, as you divest a product like ADDYI, there is -- which was a negative EBITDA, that will be a positive or certainly neutral for 2018 as we no longer have that asset. So those are some of the things that I would say on our cost-cutting relative. I think that's about as far as I can go on -- can't say too much more about '18.

    當然。關於配藥完成率以及我們在——領取我們處方的患者身上所看到的情況,我想說的是,我們確實有相關數據。我們正在觀察——我把這整體稱為依從性(compliance),也就是患者如何配藥、如何按處方取藥。我們會檢查這一點,特別是在我們所有的慢性用藥上,例如 XIFAXAN。我們已經建立了多項計畫,我們認為我們正在推動一些能提升患者依從性的計畫。這類計畫——尤其是像我們在 SILIQ 上與專科藥局合作所做的——都是為了協助患者,並確保我們能改善這一點。但我們——這確實是我們持續關注的事項。我們目前沒有看到太多挑戰,但這是我們一直在密切留意的,David。至於解決訴訟的問題,我——我不知道我是否能比我們在簡報中所說的再多講些什麼。Christina Ackermann 以及她的法務團隊做得非常出色。如果你想想從第二季財報電話會議到現在,我們解決了 21 件訴訟或法律事項,我們認為這是非常了不起的成就,這要很大程度歸功於團隊在我們逐一處理過程中的努力。我們所辨識出的議題,我的意思是,每一項都在投影片中,我認為對我們而言都是非常重要的事項。例如,如果你想到——我們曾辨識出一件 GLUMETZA 的案件。我們一直在與對方合作。不知何故,他們提起了訴訟。不過我們確實很快就解決了,把它拋在身後,而這正是我們處理方式中最重要的一點。凡是能解決的案件,我們就會解決,並在所有訴訟上持續向前推進。但顯然,對於我們相信自己有正確立場的案件,我們會嚴格、有力地進行抗辯,我們也會這麼做——不論是任何類型的訴訟或智慧財產權案件。至於你問題最後一部分的成本削減,我們已經做了很多。我們在 2016、2017 年已經削減了接近 1 億美元的營運費用。隨著我們在 2017 年已剝離的資產,我們將持續檢視公司還能在哪些地方降低營運費用,以確保把資源投入到我之前所說的核心業務。我們認為投資報酬率最佳、最能帶動成長的領域,將是我們成本削減聚焦的方向。顯然,當你剝離像 ADDYI 這樣的產品時——它原本是 EBITDA 為負——在 2018 年,因為我們不再持有該資產,這將轉為正面或至少中性。以上是我對我們成本削減相關的一些說明。我想我能談的大概就到這裡——關於 2018 年我不能再多說太多。

  • Operator

    Operator

  • Our final question comes from Chris Schott of JPMorgan.

    我們最後一個問題來自摩根大通(JPMorgan)的 Chris Schott。

  • Christopher Z. Neyor - Analyst

    Christopher Z. Neyor - Analyst

  • This is Chris on for Chris. First one's on Salix. Recently, you had adverse District Court ruling on the patent for UCERIS. Could you just talk about the impact of that for Salix, and maybe the timing and overall expectation for a competitive product launch? And then secondly, on Ortho Dermatologics. Could you maybe talk about IDP-121 and 122 and how you see those fitting into the marketplace over time? And then also, bigger picture, how are you thinking about peer access and pricing given current pressures in the derm market?

    我是 Chris,代 Chris 提問。第一個問題關於 Salix。最近,您們在 UCERIS 專利方面遭遇地方法院(District Court)的不利裁決。您能否談談這對 Salix 的影響,以及競品上市的時點與整體預期?第二個問題關於 Ortho Dermatologics。您能否談談 IDP-121 與 122,以及您如何看待它們隨時間在市場中的定位?另外,從更宏觀的角度,在皮膚科市場目前的壓力下,您們如何看待同儕可及性(peer access)與定價?

  • Joseph C. Papa - Chairman & CEO

    Joseph C. Papa - Chairman & CEO

  • Okay. I'll do my best to catch all 3 of them. So let me start with the UCERIS question. As you know, there was some intellectual property challenges on the UCERIS. The judge issued his opinion in late October. We have looked at that opinion. We certainly plan to appeal that ruling on the opinion of the judge. However, I think it's important to say that in any product case where certainly there's intellectual property, another important aspect of that is whether or not a company or one of the generic companies has an approval. To our knowledge, according to FDA publications, no company currently has an FDA approval to market a generic version of UCERIS. We think that's an, probably, as important part of this question as we think about whether or not somebody can come to the marketplace. So we are looking at the intellectual property. We will defend our intellectual property. But the other important comment certainly is the lack of any regulatory approval at this time relative to a generic ability to market a generic version of UCERIS. On the question of the Ortho Dermalogics business, once again, we're excited. We think 121 and 122 in addition to 118 are all very good opportunities for us. We have 121, it has, as I mentioned in my public comments, we've had a chance to file that one for acne. We do think it has a very good opportunity to continue to expand our Retin-A portfolio with a new formulation. And then 122 as a product is a, once again, it's a high-dose or high-potency corticosteroid in a very unique formulation that's got very good results. You can see some of the results of -- as I presented 118, 122 is a component of the 118. So we think that's the other reason why we have a high-potency corticosteroid opportunity that has a very unique formulation that we think is going to help for those patients with psoriasis. And the final question was on pricing. I'm sorry, repeat the last part of the pricing question?

    好的。我會盡力把這三個問題都回答到。我先從 UCERIS 的問題開始。如你所知,UCERIS 面臨一些智慧財產權方面的挑戰。法官在 10 月下旬發布了他的意見。我們已經審視了該意見。我們當然計畫就法官的意見所作出的裁決提出上訴。不過,我認為重要的是要指出,在任何產品案件中,尤其涉及智慧財產權時,另一個重要面向是某家公司或某家學名藥公司是否已取得核准。據我們所知,根據 FDA 的公開資料,目前沒有任何公司取得 FDA 核准可行銷 UCERIS 的學名藥版本。在我們思考是否有人能進入市場時,我們認為這可能是——大概——與此問題同等重要的一部分。因此,我們正在處理智慧財產權議題。我們會捍衛我們的智慧財產權。但另一個重要的評論當然是:就學名藥能否行銷 UCERIS 的學名版本而言,目前並沒有任何監管核准。至於 Ortho Dermalogics 業務的問題,再次強調,我們感到很振奮。我們認為 121 和 122,加上 118,對我們而言都是非常好的機會。關於 121,正如我在公開評論中提到的,我們已經有機會就痤瘡(acne)適應症提交申請。我們確實認為它有很好的機會,透過新的劑型持續擴展我們的 Retin-A 產品組合。而 122 這個產品,再次強調,它是一種高劑量或高效價(high-potency)的皮質類固醇,採用非常獨特的配方,且結果非常好。你可以看到一些結果——就像我所展示的 118,122 是 118 的一個組成成分。因此,我們認為這也是另一個原因:我們擁有一個高效價皮質類固醇的機會,且其配方非常獨特,我們認為這將有助於那些乾癬(psoriasis)患者。最後一個問題是關於定價。抱歉,請重複一下定價問題的最後一部分?

  • Christopher Z. Neyor - Analyst

    Christopher Z. Neyor - Analyst

  • Yes. So I guess, for the topical ones that you have in dermatology, how are you thinking about peer access and pricing just given current dynamics in the derm market?

    是的。所以我想問,針對你們在皮膚科的外用產品,考量到目前皮膚科市場的動態,你們如何看待同儕可及性(peer access)以及定價?

  • Joseph C. Papa - Chairman & CEO

    Joseph C. Papa - Chairman & CEO

  • Sure. Thank you. Sorry, just the 3 questions, I got the first 2. I knew it was pricing. On the question on pricing, we haven't set any pricing to be clear. But think of it this way, and I'm going to start with IDP-118 because I think it's probably the easiest way to start. Unfortunately, patients with psoriasis need long-term chronic treatment. Many patients go on to biologics. If we, with IDP-118, can offer patients either a delayed start to the biologic and/or for that patient who's on biologic but unfortunately still has a breakthrough and, let's call it, on their elbow just for the sake of argument, and they can treat that breakthrough in that area by the use of the IDP-118, that's, we think, a very significant opportunity for the patient to get the 100 -- potential 100% clearance to the skin. Obviously, we are going to SILIQ. We do think we have good efficacy and a PASI 100. But just some of the drugs, they don't have the PASI 100 results. Therefore, we think we can supplement the biologic with our product potentially, depending on FDA approval, and allow the patient to get that better clearance for their skin. So relative to pricing, we haven't set any specific pricing, but we do think there's opportunities there, especially to make our products very cost-effective versus the alternative for patients who have psoriasis. That's probably about as far as I can say right now on pricing. We'll have a lot more to say as we bring out these new products.

    當然。謝謝。抱歉,就這3個問題,我前2個聽到了。我知道其中一個是定價。關於定價這個問題,先說清楚,我們尚未設定任何定價。但可以這樣想,我先從IDP-118開始,因為我認為這可能是最容易切入的方式。很不幸地,乾癬患者需要長期的慢性治療。許多患者最後會使用生物製劑。如果我們透過IDP-118,能讓患者延後開始使用生物製劑,和/或對於已在使用生物製劑但不幸仍出現復發(姑且以手肘為例)的患者,能用IDP-118在該區域治療這次復發,我們認為這對患者而言是非常重大的機會,有望讓皮膚達到100%——潛在的100%清除。顯然,我們會以SILIQ作為參照。我們確實認為我們有良好的療效,並且可達到PASI 100。但有些藥物並沒有PASI 100的結果。因此,我們認為在獲得FDA核准的前提下,我們的產品可能可以補充生物製劑的治療,讓患者的皮膚達到更好的清除效果。所以就定價而言,我們尚未設定任何具體定價,但我們確實認為存在機會,尤其是讓我們的產品相較於乾癬患者的替代方案更具成本效益。關於定價,我目前大概只能說到這裡。隨著我們推出這些新產品,我們會有更多內容可以分享。

  • But let me conclude with thanks everybody. Thank you very much for joining us today. We're really excited about the opportunities in front of us. I think you could hear the excitement from myself and from Paul. We want to thank all of the employees, the Valeant organization for what they've done to help continue to build the strength of this business and turnaround the Valeant company.

    不過讓我在最後向各位致謝。非常感謝各位今天加入我們。我們對眼前的機會感到非常振奮。我想你們也能聽出我和Paul的興奮之情。我們要感謝所有員工,以及Valeant組織,感謝他們所做的一切,協助我們持續強化這項業務的實力,並推動Valeant公司的扭轉。

  • We'll conclude the call right now. Thank you. Thank you very much for joining us today. Have a great day, everyone.

    我們現在就結束本次電話會議。謝謝。非常感謝各位今天加入我們。祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's conference call. You may now disconnect.

    本日電話會議到此結束。您現在可以掛線。